Alkem Laboratories Announces 51st AGM and Reports Strong FY2025 Financial Performance
The announcement includes comprehensive financial results for FY2025, details on significant strategic acquisitions that diversify the company's portfolio, and updates on key growth platforms like biosimilars and MedTech, all of which are material to the company's future performance and valuation.
The company reported strong financial growth in revenue, PAT, and EBITDA, significant strategic acquisitions expanding its portfolio into high-growth areas (derma cosmetology, orthopaedics, biosimilars), successful regulatory inspections, and a positive outlook from management on future growth initiatives.
Alkem Laboratories Limited announced its 51st Annual General Meeting (AGM) will be held on Monday, 25th August, 2025, at 11:00 a.m. via Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The company also released its Annual Report for the financial year 2024-2025.
Key highlights from the FY2025 Annual Report include: * Revenue from Operations increased by 2.3% year-on-year to ₹12,964.5 crore. * Profit After Tax (PAT) rose by 20.6% year-on-year to ₹2,165.5 crore. * EBITDA increased by 11.9% year-on-year to ₹2,512.2 crore, with EBITDA margins expanding from 17.7% to 19.4%. * The company reported a strong net cash position of ₹4,620 crore. * Domestic sales grew by 6.5% year-on-year to ₹8,983.7 crore, with the company outperforming the Indian Pharmaceutical Market (IPM) in key therapy areas like Gynaecology, Respiratory, Gastrointestinal, and VMN. * Non-US international business recorded an 8.7% growth. * R&D spend stood at ₹562 crore, reflecting commitment to innovation. * Alkem successfully closed USFDA inspections at its Baddi and Taloja R&D Centre, reaffirming its capability to meet global standards. * The company made strategic acquisitions of Adroit Biomed in derma cosmetology and Bombay Ortho in orthopaedics, marking its entry into adjacent high-growth areas. * Significant progress was made in the biosimilars platform (Enzene Biosciences), including the upcoming biologics CDMO facility in New Jersey. * Alkem formally entered the medical devices segment through Alkem MedTech, with the acquisition of a manufacturing facility for orthopaedic implants and technology transfer from a US partner.
Management comments emphasized the company's evolution into a professionally governed, performance-driven organization, with a focus on strengthening the present and building for the future through strategic investments in high-impact verticals like biologics and MedTech, while maintaining cost discipline and global expansion.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under regulatory filings. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.